SCHEMBL4385210

SCHEMBL4385210

O=c1ccc(C(ON=C2CCN(S(=O)(=O)c3ccc(OC(F)(F)F)cc3)CC2)c2ccc(F)cc2)c[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
SCN9A Q15858 1/20 0.38
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
EPHX2 P34913 2/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
CYP2C9 P11712 1/20 0.34
PKM P14618 1/20 0.34
EPHX1 P07099 2/20 0.34
HDAC3 O15379 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4385227 0.91 MEN1 (0.49) LIPEMEN1KMT2ASCN9AEPHX2
SCHEMBL8218879 0.83 MEN1 (0.43) LIPEMEN1KMT2ASCN9ATSHR
SCHEMBL4385770 0.82 KMT2A (0.58) LIPEMEN1KMT2ASMN1; SMN2EPHX2
SCHEMBL4381279 0.82 PKM (0.49) MEN1KMT2ACYP2C9PKM
SCHEMBL8219208 0.80 KMT2A (0.42) LIPEMEN1KMT2ASCN9APKM
SCHEMBL4391227 0.80 SCN9A (0.47) MEN1KMT2ASCN9ATSHRCYP2C9
SCHEMBL4386311 0.79 MEN1 (0.43) LIPEMEN1KMT2ASCN9APSEN1
SCHEMBL8220357 0.79 LIPE (0.46) LIPEMEN1KMT2ASCN9AEPHX2
SCHEMBL4391478 0.79 PKM (0.52) MEN1KMT2ATSHRSMN1; SMN2PKM
SCHEMBL4386376 0.78 ALDH1A1 (0.43) MEN1KMT2ASMN1; SMN2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 LIPE 2501/4885MEN1 3694/4885KMT2A 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.